Today on THCB Spotlights, Matthew sits down with Paul Johnson, the CEO of Lemonaid. Lemonaid just closed a $33 million Series B led by Olive Tree Ventures, expanding their direct-to-consumer online services which provide primary care visits as well as pharmacy and medication delivery to your home and launching into more chronic areas of care, such as hypertension, high cholesterol, asthma and type 2 diabetes. Why did they wind up with an Israel-focused lead investor in Olive Tree as a San Francisco-based company? Where is Lemonaid in terms of growth and revenue? And how is Lemonaid differentiating itself against some of the other chronic care management and telehealth companies? Find out how the company aims to provide care for patients holistically and be the first point of contact for patients in seeking healthcare.